The effect of mesoporphyrin on the production of cytokines by inflammatory cells in vitro

Japanese Journal of Pharmacology

Volumn 80, Issue 1, 1999, Pages 33-40

  Takaoka, Yuko ^a   Matsuura, Satoko ^a   Boda, Keiko ^a   Nagai, Hiroichi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Cyclooxygenase activity; Interferon ; Mesoporphyrin

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; INDOMETACIN; INTERLEUKIN 4; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MESOPORPHYRIN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PREDNISOLONE; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HELPER CELL; INFLAMMATORY CELL; MACROPHAGE; MOUSE; NONHUMAN; OSTEOBLAST; T LYMPHOCYTE SUBPOPULATION;

EID: 0032974897     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.80.33     Document Type: Article

References (46)

1. An Y, Irma G and Kim EB: Dual effects of protoporphyrin and long wave ultraviolet light on histamine release from rat peritoneal and cutaneous mast cells. J Immunol 144, 4327-4332 (1990)
2. Stepien H, Kunert-Radek J, Stanisz A, Zerek-Melen G and Pawlikowski M: Inhibitory effect of porphyrins on the proliferation of mouse spleen lymphocytes in vitro. Biochem Biophys Res Commun 174, 313-322 (1991)
3. Bradley JN, James LE, Sonya M, Fischer A, and Mrendan JC: Inhibition by zinc protoporphyrin-IX of vasoactive interstinal peptide-induced relaxations of guinea pig isolated trachea. J Pharmacol Exp Ther 378, 964-970 (1996)
4. Ueno Y, Haga M, Kondo T, Iwata S, Omori S, Takaoka A, Fukumoto K, Kondo T, Takasaki H and Yamada T: The effect of protoporphyrin disodium on liver diseases. Ther N Drugs 15, 3079-3088 (1984)
5. Sakata T and Endo T: Long term treatment of protoporphyrin disodium on chronic hepatitis and liver cirrhosis. Pharmacol Rev 12, 5221-5227 (1984)
6. Nagai H, Takaoka Y, Mori H and Matsuura N: The effects of mesoporphyrin on experimental arthritis in mice. Inflamm Res 45, 293-298 (1996)
7. Zvaifler NJ and Firestein GS: Pannus and pannocyte: alternative models of joint destruction in rheumatoid arthritis. Arthritis Rheum 37, 783-789 (1994)
8. Mulherin D, Fitzgerald O and Bresnihan: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 39, 115-124 (1996)
9. Ishikawa H and Ziff M: Electron microscopic observations of immunoreactive cells in rheumatoid synovial membrance. Arthritis Rheum 19, 1-14 (1976)
10. Meijer CJLM, deGraaf-Reitsma CB, Lafeber GJM and Cats AV: In situ location of lymphocyte subsets in synovial membranes of patients with rheumatoid arthritis using monoclonal antibodies. J Rheumatol 9, 359-369 (1982)
11. Kurosawa M and Ziff M: Immunoelectron microscopic study of the distribution of T cell subsets in rheumatoid synovium. J Exp Med 158, 1191-1210 (1983)
12. Hernderson B and Pettipher ER: The synovial lining cell: biology and pathology. Semin Arthritis Rheum 15, 1-32 (1985)
13. Mapp PI and Revell PA: Ultrastructural characterization of macrophages (type A cells) in the synovial lining. Br J Rheumatol 8, 171-176 (1988)
14. Dayer JM, de Rochemonterix B, Burrus B, Demczuk S and Dinarello CA: Human recombinant interleukin-1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 77, 645-648 (1986)
15. Leizer T, Clarris BJ, Ash PE, Van Damme J, Saklatvala J and Hamilton JA: Interleukin-1α and interleukin-1β stimulate synovial fibroblast plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum 30, 562-566 (1987)
16. Buchan G, Barrett K, Turner M, Chantry D, Maini RN and Feldmann M: Interleukin-1 and tumor necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1α. Clin Exp Immunol 73, 449-455 (1988)
17. Firestein GS, Alvaro-Garcia JM and Maki R: Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 144, 3347-3353 (1990)
18. Wood NC, Symons JA, Dickens E and Duff GW: In situ hybridization of in rheumatoid arthritis. Clin Exp Immunol 87, 183-189 (1992)
19. Guerne PA, Zuraw BL, Carson DA and Lotz M: Synovium as a source of interleukin-6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 83, 585-592 (1989)
20. Dolhain RJEM, van der Heiden AN, ter Haar NT, Breedveld FC and Miltenburg AMM: Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 39, 1961-1969 (1996)
21. Yin Z, Braun J, Neure L, Wu P, Eggens U, Krause A, Kamrad T and Sieper J: T cell cytokine pattern in the joints of patients with lyme arthritis and its regulation by cytokines and anti-cytokines. Arthritis Rheum 40, 69-79 (1997)
22. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA and Coffman RL: Two types of murine helper T-cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136, 2348-2357 (1986)
23. Killar L, MacDonald G, Jeff W, Woods A and Bottomly K: Cloned Iα-restricted T cells that do not produce interleukin-4 (IL-4)/B cell stimulatory factor 1 (BSF-1) fail to help antigen-specific B cells. J Immunol 138, 1674-1679 (1987)
24. O'Neill GP and Ford-Hutchinson: Expression of mRNA for cyclooxygenase-1 and cyclooxygenase-2 in human tissues. FEBS Lett 330, 156-160 (1993)
25. Keller ET and Ershler WB: Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol 154, 4091-4098 (1995)
26. Futaki N, Takahashi S, Yokoyama M, Arai I, Higuchi S and Otomo S: NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthetase/cyclooxygenase (COX-2) activity in vitro. Prostaglandins 47, 55-59 (1994)
27. Wilder RL: Hormones, pregnancy and autoimmune diseases. Ann NY Acad Sci 840, 45-50 (1998)
28. Isomaki P and Punnonen J: Pro- and anti-inflammatory cytokines in rheumatoid arthritis. Ann Med 29, 499-507 (1998)
29. Gomez-Reino J, Miller F and Meiselas L: In vitro response of peripheral blood lymphocytes from patients with rheumatoid arthritis to lipopolysaccharides. J Lab Clin Med 95, 335-342 (1980)
30. Res RC, Orsini DL, Van Laar JM, Janson AA, Abou-Zeid C and Vries RR: Diversity in antigen recognition by mycobacterium tuberculosis-reactive T cell clones from synovial fluid of rheumatoid arthritis patients. Eur J Immunol 21, 1297-1302 (1991)
31. Cutolo M, Sulli A, Barone A, Seriolo B and Accardo S: Sex hormones, proto-oncogene expression and apoptosis: their effects on rheumatoid synovial tissue. Clin Exp Rheumatol 14, 87-94 (1996)
32. Kohno H, Shigeno C, Kasai R, Akiyama H, Iida H, Tsuboyama T, Sato K, Konishi J and Nakamura T: Synovial fluids from patients with osteoarthritis and rheumatoid arthritis contain high levels of parathyroid hormone-related peptide. J Bone Miner Res 12, 847-854 (1997)
33. Joosten LAB, Helsen MMA, van de Loo FAJ and vanden Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. Arthritis Rheum 39, 797-809 (1996)
34. Williams RO, Feldmann M and Maini RN: Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci USA 89, 9784-9788 (1992)
35. Elliott MJ, Maini RN, Feldman M, Bijl H, Ghrayeb J and Woody JN: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α. Arthritis Rheum 36, 1681-1690 (1993)
36. Elliott MJ, Maini RN, Feldman M, Kalden JR, Antoni C, Smolen J, Leeb B, Breedveld EC, Macfarlane JD, Bijl H and Woody JN: Randomised double-blind comparison of chemeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344, 1105-1110 (1994)
37. Williams RO, Williasms DG, Feldmann M and Maini RN: Increased limb involvement in murine collagen-induced arthritis following treatment with anti-interferon-gamma. Clin Exp Immunol 92, 323-328 (1993)
38. Biossier MC, Chiocchia G, Bessis N, Hajunal H, Garotta G, Nicoletti F and Fournier C: Biphasic effect of interferon-γ in murine collagen-induced arthritis. Eur J Immunol 25, 1184-1190 (1995)
39. Schulze-Koops H, Lipsky PE, Kavanaugh AF and Davis LS: Elevated Th1-or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis: modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol 155, 5029-5037 (1995)
40. Alonzi T, Fattori E, Lazzaro D, Costa P, Probert L, Kollias G, De Benedetti F, Poli V and Ciliberto G: Interleukin-6 is required for the development of collagen-induced arthritis. J Exp Med 187, 461-468 (1998)
41. Rosenbaum JT, Cugnini R, Tara DC, Hefeneider S and Ansel JC: Production and modulation of interleukin-6 synthesis by synoviocytes derived from patients with arthritic disease. Ann Rheum Dis 51, 198-202 (1992)
42. Kennedy AC and Lindsay R: Bone involvement in rheumatoid arthritis. Clin Rheum Dis 3, 403-420 (1977)
43. Sambrook PN, Eisman JA, Champion JD, Yeates MD, Pocock NA and Ebrl S: Determinants of axial bone loss in rheumatoid arthritis. Arthritis Rheum 30, 721-728 (1987)
44. Ishimi Y, Miyaura C, Jin CH, Akatsu T, Abe E, Nakamura Y, Yamaguchi A, Yoshiki S, Matsuda T, Hirano T, Kishimoto T and Suda T: IL-6 is produced by osteoblasts and induces bone resorption. J Immunol 145, 3297-3303 (1990)
45. Inoue K, Fujisawa H, Motonaga A, Inoue Y, Kyoi T, Ueda F and Kimura K: Anti-inflammatory effects of etodlac: comparison with other non-steroidal anti-inflammatory drugs. Biol Pharm Bull 17, 1577-1583 (1994)
46. Inoue K, Motonaga A, Nishimura Y, Yokota M, Miki N, Fujisawa H, Ueda F, Shibata Y and Kimura K: Medianism of anti-inflammatory action of etodlac. Arzneimittelforshung 41, 228-235 (1991)